Market Overview

Milberg LLP Announces Pendency of Class Action Lawsuits Filed Against Peregrine Pharmaceuticals

Share:
Related PPHM
Earnings Scheduled For July 14, 2015
Peregrine Pharmaceuticals Granted Key European Patent for Its Lead Clinical Drug Candidate Bavituximab

Milberg LLP announces that class action lawsuits were filed in the United States District Court for the Central District of California on behalf of purchasers of Peregrine Pharmaceuticals, Inc. (“Peregrine”) (NASDAQ: PPHM) common stock during the period July 16, 2012 to September 26, 2012, (the “Class Period”).

Milberg LLP has created a website (http://www.PeregrineLawsuit.com) that seeks to answer common questions about shareholder class actions.

Posted-In: News FDA

 

Related Articles (PPHM)

Get Benzinga's Newsletters